Camurati-Engelmann disease

Camurati-Engelmann disease (CED), also known as progressive diaphyseal dysplasia or Engelmann disease, is a rare genetic bone disorder characterized by progressive thickening (hyperostosis) and widening (sclerosis) of the shafts (diaphyses) of long bones, particularly the femur, tibia, and humerus. The condition is caused by mutations in the TGFB1 gene, which encodes transforming growth factor beta-1, a protein that plays a critical role in bone remodeling and formation. The disease primarily affects the skeletal system but can also impact the muscular and neurological systems. Key clinical features typically begin in childhood and include limb pain, muscular weakness, a waddling gait, easy fatigability, and reduced muscle mass, particularly in the legs. Affected individuals may also develop a characteristic body habitus with thin limbs and reduced subcutaneous fat. Thickening of the skull bones can occur, potentially leading to cranial nerve compression, which may cause facial palsy, hearing loss, or visual disturbances. Some patients experience hepatosplenomegaly and elevated erythrocyte sedimentation rate. The severity of the disease is highly variable, even within the same family. Treatment is primarily symptomatic. Corticosteroids, particularly prednisone and deflazacort, have been shown to be effective in reducing bone pain and improving muscle strength and fatigue in many patients, likely through their ability to counteract the effects of excess TGF-beta 1 signaling. Losartan, an angiotensin II receptor blocker, has also been explored as a potential therapeutic option due to its ability to reduce TGF-beta signaling. Surgical intervention may be necessary in cases of severe cranial nerve compression. Physical therapy and pain management are important supportive measures. Regular monitoring with imaging and audiological assessments is recommended.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Camurati-Engelmann disease